Sygnature Discovery appoints Susanne Back as Head of In Vivo Pharmacology
She brings 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River
She brings 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River
The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks
The CDMO Leadership Awards spotlight top-performing development and manufacturing service providers
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
The partnership has already launched with five active development programs, with both organizations jointly managing regulatory strategy and documentation under a structured, milestone-gated framework
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
The presentations underscore the company’s deep expertise in dermatology and immunology
The campaign highlights a straightforward, achievable approach to health, proving that supporting your wellness doesn’t have to be complicated
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
Subscribe To Our Newsletter & Stay Updated